Background: Premature infants benefit from human milk fortifiers for optimal growth, nutrition, neural development and reducing complications. However, the ideal timing for HMF introduction is still debated due to preterm infant’s immature digestive system and inconclusive study results, often marred by methodological flaws.

Objectives: To compare the effects of early human milk fortification (EHMF) vs late human milk fortification (LHMF) on low birth-weight (LBW) preterm neonates.

Methods: A systematic search for Randomized controlled trials comparing EHMF vs LHMF on LBW preterm neonates was conducted, covering databases such as Cochrane CENTRAL, Pubmed, Google Scholar and clinical trials registries iCRTP, ISRCTN and HERDIN from January 2000 to July 2024. Statistical analysis was performed using Review Manager version 5.3, with mean differences for continuous outcomes and risk ratio (RR) for dichotomous outcomes. A sensitivity analysis using the leave-one-out method and meta-regression was conducted to address potential confounding factors and publication biases were assessed through funnel plots.

Results:The EHMF group showed potential benefits in reducing the incidence of retinopathy of prematurity (ROP) and neonatal sepsis, achieving a faster time to regain birth weight. However, there may be an increased risk of bronchopulmonary dysplasia and the effects of necrotizing enterocolitis and feeding intolerance (FI) may be unclear. Interestingly, given the high precision of pooled effects on growth, hospital outcomes (length and time to reach full feeds) and adverse effects (extra-uterine growth restriction) no significant difference between groups were noted.

Conclusions:The study suggests that EHMF could impact growth parameters and reduced adverse outcomes, although most effects were not significant. The wide confidence intervals around some effect sizes suggest a need for more robust studies to resolve these uncertainties.

Human ; Male ; Female

INTRODUCTION: Hypertension is a key modifiable risk factor for myocardial infarction and stroke, yet medication adherence remains low. The ongoing COVID-19 pandemic has further complicated the management of chronic diseases like hypertension. This study aimed to explore the correlation between the patient-doctor relationship and medication adherence among hypertensive Filipinos aged 40-65 years in the Greater Manila Area during the pandemic. METHODS: A cross-sectional study was conducted involving 131 hypertensive Filipino participants. Data were collected through an online survey, assessing participant demographic and medical profiles, medication adherence using the Hill-Bone Compliance Scale (HBCS), and the patient-doctor relationship using the Physician-Doctor Relationship Questionnaire-9 (PDRQ-9). RESULTS: Approximately half of the participants demonstrated good adherence to hypertension medication. A weak but significant positive correlation was found between overall medication adherence and the patient-doctor relationship. The duration of anti-hypertensive drug intake also showed a weak positive correlation with medication adherence. Factors such as comorbidities and type of consultation did not significantly impact medication adherence. CONCLUSION This study emphasizes the significance of the patient-doctor relationship in medication adherence among hypertensive Filipinos during the COVID-19 pandemic. Enhancing communication and trust between patients and physicians can potentially improve medication adherence and overall disease management.
COVID-19 ; hypertension ; medication adherence ; perception ; anti-hypertensive agents ; cross- sectional